Development of peptide fusion inhibitors targeting HIV-1 gp41 - 文章详情页

作者：

Ma, Xue Ting (Ma, Xue Ting.) | Sun, Xiao Hui (Sun, Xiao Hui.) | Tan, Jian Jun (Tan, Jian Jun.) | Wang, Cun Xin (Wang, Cun Xin.)

收录：

EI Scopus

摘要：

HIV-1　membrane　fusion　plays　an　important　role　in　the　process　that　HIV-1　entrys　cells.　As　a　new　treatment　options　targeting　HIV-1　entry　process,　fusion　inhibitors　have　been　proposed.　Peptide　T20　which　derived　from　viral　envelope　glycoprotein　gp41,　is　the　first　and　only　HIV-1　fusion　inhibitor　approved　by　the　FDA.　Currently,　a　large　number　of　prospective　fusion　peptides　have　emerged.　This　paper　introduced　the　possible　mechanism　of　fusion　inhibitor,　reported　the　current　developments　and　innovative　designs　of　HIV-1　membrane　fusion　inhibitors.　©　2013　Springer-Verlag.

关键词：

Biomedical engineering Cell membranes Mechanisms Medical Physics Peptides

作者机构：

[ 1 ] [Ma, Xue Ting]College of Life Science and Bio-engineering, Beijing University of Technology, No. 100 Pingleyuan street, Chaoyang District, Beijing 100124, China
[ 2 ] [Sun, Xiao Hui]College of Life Science and Bio-engineering, Beijing University of Technology, No. 100 Pingleyuan street, Chaoyang District, Beijing 100124, China
[ 3 ] [Tan, Jian Jun]College of Life Science and Bio-engineering, Beijing University of Technology, No. 100 Pingleyuan street, Chaoyang District, Beijing 100124, China
[ 4 ] [Wang, Cun Xin]College of Life Science and Bio-engineering, Beijing University of Technology, No. 100 Pingleyuan street, Chaoyang District, Beijing 100124, China

通讯作者信息：

电子邮件地址：

tanjianjun@bjut.edu.cn

查看成果更多字段

成果类型
所属机构

所有年份指定年份从至